testo-alternativo
Clear Skin Ahead: Breakthroughs in Psoriasis Care

Advancements in Dermatology: A Weekly Review

Dermatologia e Venerologia

Clear Skin Ahead: Breakthroughs in Psoriasis Care

From the hidden psychological toll to next-gen biologics and AI-driven treatments, discover how psoriasis research is redefining autoimmune care and offering new hope for patients worldwide.

Login or Register to listen to this episode

Bibliography

Psychological impact – O’Leary C. highlights significant psychological distress in psoriasis patients (Br J Hosp Med, 2025).


Long-term biologic efficacy – Bimekizumab maintains efficacy up to 196 weeks with sustained safety (Blauvelt A et al., J Am Acad Dermatol, 2025).


Phototherapy in skin of color – Narrowband UV-B remains effective across diverse skin types (Hauptman M et al., Photodermatol Photoimmunol Photomed, 2025).


Pediatric burden – Systematic review underscores substantial quality-of-life impact in children (Yang A et al., Am J Clin Dermatol, 2025).


Early psoriatic arthritis detection – Ultrasound proves valuable for intercepting psoriatic arthritis in psoriasis patients (Possemato N et al., Clin Exp Rheumatol, 2025).


Immune microenvironment – Overview of bench-to-bedside insights into skin immunity in psoriasis (Yao Y et al., Front Immunol, 2025).


Real-world Ixekizumab data – Evidence supports efficacy in psoriasis, psoriatic arthritis, and axial spondyloarthritis (Puig L et al., Adv Ther, 2025).


Thromboembolism risk – Meta-analysis and Mendelian randomization show a link between psoriasis and venous thromboembolism (Yang M et al., Medicine (Baltimore), 2025).


Treatment across skin tones – Guselkumab effective in moderate-to-severe psoriasis in all skin types (Alexis A et al., JAMA Dermatol, 2025).


Subcutaneous methotrexate – Comprehensive review confirms safety and efficacy for moderate-to-severe plaque psoriasis (Viguier M et al., Int J Dermatol, 2025).

Comments

Please Login to leave a comment.

No comments yet. Be the first to comment!